News

How CLL evades the immune system


 

Fabienne Mackay, PhD

Photo courtesy of

Monash University

A study published in Leukemia has revealed a mechanism by which chronic lymphocytic leukemia (CLL) evades the immune system.

“It turns out that cancer cells are very good at sabotaging the immune system, using various tricks that confuse immune cells and ‘smoke screens’ preventing immune cells from recognizing the cancer,” said study author Fabienne Mackay, PhD, of Monash University in Melbourne, Victoria, Australia.

She and her colleagues believe they have determined exactly how CLL confuses the immune system and devised a way to stop it without destroying the patient’s immune system.

The team noted that B cells rely on the protein BAFF to survive. And each B cell has 3 different kinds of receptors that detect the presence of BAFF in the blood—TACI, BAFF-R, and BCMA.

The researchers discovered that, in CLL patients, the TACI receptors of cancerous B cells over-produce interleukin-10 (IL-10), which tricks the immune system into thinking nothing is wrong, allowing CLL to thrive undetected.

“We found that, when the receptor called TACI was blocked, it prevented the secretion of IL-10 without eliminating normal B cells,” Dr Mackay said. “Without IL-10, the tumor can no longer keep the immune system at bay, which means the patient’s immune system can be ‘kick-started’ again to fight infections and cancers.”

“This is very exciting because it means that B cells stay alive and well to do their job in the immune system fighting other infections. It also means the over-production of IL-10 is stopped, and the CLL cells are now exposed to immune cells specialized in fighting cancers.”

Dr Mackay said her team’s discovery may be relevant for cancers other than CLL and could change the way they are treated.

“The best weapon we have for fighting cancer is the immune system itself,” Dr Mackay noted. “It can sense the presence of an infection but also the emergence of a cancer.”

Recommended Reading

R-ISS identifies three survival patterns in multiple myeloma
MDedge Hematology and Oncology
Pretransplant support helps cancer patients sleep better
MDedge Hematology and Oncology
Febuxostat better than allopurinol for preventing tumor lysis syndrome
MDedge Hematology and Oncology
Selinexor dose lowered due to sepsis in AML patients
MDedge Hematology and Oncology
Groups draft guidelines for acute leukemia
MDedge Hematology and Oncology
How religion affects well-being in cancer patients
MDedge Hematology and Oncology
Lenalidomide can treat pulmonary sarcoidosis in MDS
MDedge Hematology and Oncology
Physical activity can benefit kids with cancer
MDedge Hematology and Oncology
Newfound mechanism could be used to fight cancers
MDedge Hematology and Oncology
How a molecule turns B cells into macrophages
MDedge Hematology and Oncology